Trial Profile
A Randomized, Parallel-group, Placebo-controlled, Double-blind Phase 1/2a Study in Healthy HIV Uninfected Adults to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost Regimens: Priming With Tetravalent Ad26.Mos4.HIV and Boosting With Tetravalent Ad26.Mos4.HIV and Either Clade C gp140 Plus Adjuvant OR a Combination of Mosaic and Clade C gp140 Plus Adjuvant
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Nov 2022
Price :
$35
*
At a glance
- Drugs Ad26 Mos4 HIV (Primary) ; HIV clade C gp140 vaccine (Primary) ; HIV mosaic gp140 vaccine (Primary) ; Aluminium phosphate
- Indications HIV infections
- Focus Adverse reactions; First in man; Pharmacodynamics
- Acronyms IPCAVD-012
- Sponsors Janssen
- 09 Nov 2022 Results assessing Safety and Immunogenicity of Ad26-vectored HIV Vaccine with Mosaic Immunogens and a Mosaic Envelope Protein in HIV-uninfected Adults published in the Journal of Infectious Diseases
- 15 Mar 2022 Planned End Date changed from 14 Sep 2023 to 4 Dec 2023.
- 15 Mar 2022 Planned primary completion date changed from 14 Sep 2023 to 4 Dec 2023.